# Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

> **NCT04328831** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 94 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **BIOLOGICAL:** IBI322

## Key facts

- **NCT ID:** NCT04328831
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-31
- **Primary completion:** 2023-08-28
- **Final completion:** 2023-08-28
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04328831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04328831, "Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04328831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*